Andrea J Passarelli1, Haley Gibbs2, Annette M Rowden3, Leigh Efird4, Elizabeth Zink5, Nestoras Mathioudakis6. 1. 1 Department of Clinical Pharmacy Services, Christiana Care Health System , Newark, Delaware. 2. 2 Department of Pharmacy, Wake Forest Baptist Medical Center , Winston Salem, North Carolina. 3. 3 Department of Pharmacy, The Johns Hopkins Hospital , Baltimore, Maryland. 4. 4 Department of Pharmacy, New York-Presbyterian Hospital Weill Cornell Medical Center , New York, New York. 5. 5 Department of Neurology, The Johns Hopkins Hospital , Baltimore, Maryland. 6. 6 Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine , Baltimore, Maryland.
Abstract
BACKGROUND: The purpose of this study was to evaluate the performance of an insulin infusion protocol targeting a blood glucose (BG) level of 140-180 mg/dL and to characterize protocol adherence. MATERIALS AND METHODS: This was a retrospective observational cohort study including patients for whom the protocol was ordered from January 2012 to May 2013. Performance metrics were assessed in all patients and in patients with an initial BG level of ≥200 mg/dL. Protocol adherence was assessed in a random subset of 50 patients without hypoglycemia and in all hypoglycemic patients. RESULTS: In patients with an initial BG level of ≥200 mg/dL, the mean time to goal was 7.1 h. The rate of decline of BG level in the first 6 h was 16.4 mg/dL/h. Mean BG level was 167 mg/dL, with 43.9% of BG values within goal and 80.3% between 80 and 199 mg/dL. The rate of hypoglycemic events was 0.14 per 100 h. The mean protocol violation rate was higher in patients with hypoglycemia compared with those without (39.8 vs. 23.5 per 100 h, P = 0.002), and 60.7% of hypoglycemic events were attributable to protocol violations. The protocol violation rate (42.8 vs. 17.6 per 100 h; P < 0.001) and the odds of hypoglycemia (odds ratio = 5.2; 95% confidence interval, 1.6, 16.5) were higher in the cardiac surgery patients compared with other patients. CONCLUSIONS: This protocol provides adequate BG control within the clinically acceptable range of 80-199 mg/dL but not within the narrower range of 140-180 mg/dL, with a low incidence of hypoglycemia. Risk factors for hypoglycemia and barriers to protocol adherence in the cardiac surgery population should be elucidated.
BACKGROUND: The purpose of this study was to evaluate the performance of an insulin infusion protocol targeting a blood glucose (BG) level of 140-180 mg/dL and to characterize protocol adherence. MATERIALS AND METHODS: This was a retrospective observational cohort study including patients for whom the protocol was ordered from January 2012 to May 2013. Performance metrics were assessed in all patients and in patients with an initial BG level of ≥200 mg/dL. Protocol adherence was assessed in a random subset of 50 patients without hypoglycemia and in all hypoglycemic patients. RESULTS: In patients with an initial BG level of ≥200 mg/dL, the mean time to goal was 7.1 h. The rate of decline of BG level in the first 6 h was 16.4 mg/dL/h. Mean BG level was 167 mg/dL, with 43.9% of BG values within goal and 80.3% between 80 and 199 mg/dL. The rate of hypoglycemic events was 0.14 per 100 h. The mean protocol violation rate was higher in patients with hypoglycemia compared with those without (39.8 vs. 23.5 per 100 h, P = 0.002), and 60.7% of hypoglycemic events were attributable to protocol violations. The protocol violation rate (42.8 vs. 17.6 per 100 h; P < 0.001) and the odds of hypoglycemia (odds ratio = 5.2; 95% confidence interval, 1.6, 16.5) were higher in the cardiac surgery patients compared with other patients. CONCLUSIONS: This protocol provides adequate BG control within the clinically acceptable range of 80-199 mg/dL but not within the narrower range of 140-180 mg/dL, with a low incidence of hypoglycemia. Risk factors for hypoglycemia and barriers to protocol adherence in the cardiac surgery population should be elucidated.
Authors: Shilpa Shetty; Silvio E Inzucchi; Philip A Goldberg; Dawn Cooper; Mark D Siegel; Shyoko Honiden Journal: Endocr Pract Date: 2012 May-Jun Impact factor: 3.443
Authors: Judith Jacobi; Nicholas Bircher; James Krinsley; Michael Agus; Susan S Braithwaite; Clifford Deutschman; Amado X Freire; Douglas Geehan; Benjamin Kohl; Stanley A Nasraway; Mark Rigby; Karen Sands; Lynn Schallom; Beth Taylor; Guillermo Umpierrez; John Mazuski; Holger Schunemann Journal: Crit Care Med Date: 2012-12 Impact factor: 7.598
Authors: Johannes Plank; Jan Blaha; Jeremy Cordingley; Malgorzata E Wilinska; Ludovic J Chassin; Cliff Morgan; Stephen Squire; Martin Haluzik; Jaromir Kremen; Stepan Svacina; Wolfgang Toller; Andreas Plasnik; Martin Ellmerer; Roman Hovorka; Thomas R Pieber Journal: Diabetes Care Date: 2006-02 Impact factor: 19.112
Authors: Christopher A Newton; Dawn Smiley; Bruce W Bode; Abbas E Kitabchi; Paul C Davidson; Sol Jacobs; R Dennis Steed; Frankie Stentz; Limin Peng; Patrick Mulligan; Amado X Freire; Angel Temponi; Guillermo E Umpierrez Journal: J Hosp Med Date: 2010-10 Impact factor: 2.960
Authors: Alexandre B Cavalcanti; Eliezer Silva; Adriano J Pereira; Milton Caldeira-Filho; Francisca P Almeida; Glauco A Westphal; Renate Beims; Caio C Fernandes; Thiago D Correa; Marcos R Gouvea; José Eluf-Neto Journal: J Crit Care Date: 2009-07-09 Impact factor: 3.425
Authors: Jeremy J Cordingley; Dirk Vlasselaers; Natalie C Dormand; Pieter J Wouters; Stephen D Squire; Ludovic J Chassin; Malgorzata E Wilinska; Clifford J Morgan; Roman Hovorka; Greet Van den Berghe Journal: Intensive Care Med Date: 2008-07-26 Impact factor: 17.440
Authors: Philip A Goldberg; Mark D Siegel; Robert S Sherwin; Joshua I Halickman; Michelle Lee; Valerie A Bailey; Sandy L Lee; James D Dziura; Silvio E Inzucchi Journal: Diabetes Care Date: 2004-02 Impact factor: 19.112
Authors: Karin Amrein; Norman Kachel; Heike Fries; Roman Hovorka; Thomas R Pieber; Johannes Plank; Urs Wenger; Barbara Lienhardt; Marco Maggiorini Journal: BMC Endocr Disord Date: 2014-07-29 Impact factor: 2.763